Use of once‐weekly semaglutide in patients with type <scp>2</scp> diabetes in routine clinical practice: Results from the <scp>SURE C</scp> anada multicentre, prospective, observational study

Abstract

In SURE Canada, patients treated with OW semaglutide in routine clinical practice experienced clinically significant improvements in HbA1c, BW and other outcomes, supporting semaglutide use in routine clinical practice.